Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission

Author:

Stoddard MadisonORCID,Novokhodko AlexanderORCID,Sarkar SharanyaORCID,Van Egeren DebraORCID,White Laura F.ORCID,Hochberg Natasha S.,Rogers Michael S.,Zetter Bruce,Joseph-McCarthy Diane,Chakravarty Arijit

Abstract

The strategy of relying solely on current SARS-CoV-2 vaccines to halt SARS-CoV-2 transmission has proven infeasible. In response, many public-health authorities have advocated for using vaccines to limit mortality while permitting unchecked SARS-CoV-2 spread (“learning to live with the disease”). The feasibility of this strategy critically depends on the infection fatality rate (IFR) of SARS-CoV-2. An expectation exists that the IFR will decrease due to selection against virulence. In this work, we perform a viral fitness estimation to examine the basis for this expectation. Our findings suggest large increases in virulence for SARS-CoV-2 would result in minimal loss of transmissibility, implying that the IFR may vary freely under neutral evolutionary drift. We use an SEIRS model framework to examine the effect of hypothetical changes in the IFR on steady-state death tolls under COVID-19 endemicity. Our modeling suggests that endemic SARS-CoV-2 implies vast transmission resulting in yearly US COVID-19 death tolls numbering in the hundreds of thousands under many plausible scenarios, with even modest increases in the IFR leading to unsustainable mortality burdens. Our findings highlight the importance of enacting a concerted strategy and continued development of biomedical interventions to suppress SARS-CoV-2 transmission and slow its evolution.

Funder

National Science Foundation Graduate Research Fellowship Program

Publisher

MDPI AG

Subject

General Medicine

Reference138 articles.

1. Writer, A.P.H.S. (Harvard Gazette, 2020). Anthony Fauci Offers a Timeline for Ending COVID-19 Pandemic, Harvard Gazette.

2. Halperin, D.T., Hearst, N., Hodgins, S., Bailey, R.C., Klausner, J.D., Jackson, H., Wamai, R.G., Ladapo, J.A., Over, M., and Baral, S. (2021). Revisiting COVID-19 Policies: 10 Evidence-Based Recommendations for Where to Go from Here. BMC Public Health, 21.

3. The Success of SARS-CoV-2 Vaccines and Challenges Ahead;Subbarao;Cell Host Microbe,2021

4. Stieg, C. (CNBC, 2021). From Vaccines to Safe Socialization: Here’s What to Expect in 2021, According to Experts, CNBC.

5. Picard, A. (The Globe and Mail, 2020). Opinion: How Will the Pandemic End? Not with a Moment of Triumph We’ll All Remember, but with a Slow Whimper We’ll Soon Forget, The Globe and Mail.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3